A company with a platform that is proven to work and deliver highly toxic warheads directly to cancer tumours with very few side effects and no cardiotoxicity isn't worth investing in.
As pointed out by the Hurstbot fans, most don't understand what he posts it's just far too clever. Always right too. IPO book build in 4 weeks added to the diary.
Funny isn't it, almost like some in the market knew there was an RNS coming today. But it wasn't the one they were expecting so they sell with thier 10% gain.